Eric Lefkofsky has spent numerous years focusing on charities. His most current endeavors are in the field of medicine. He founded Tempus because he believe effective medical care begins with data. Tempus provides data for oncologists including treatments and tumors. The company uses machine learning in the operating system to make information serviceable and accessible. This mean oncologists can identify the type of treatment best suited to different types of tumors leading to more individualized care for patients.
Eric Lefkofsky has also contributed to Rise of the Rest. Steve Case and J.D. Lance are the founders. The investors include Eric Schmidt and Jeff Bezos. The organization is concerned with the areas of the country without a well functioning technology sector. The organization believes the largest portion of seed money to establish new start ups goes directly to Silicon Valley. This leaves areas like the Rust Belt with potential and raw talent but few high tech startups. Rise of the Rest helps establish start ups in areas where technology sectors are lacking. This enables more people to be a part of American dream. When startups are located throughout the country, the expectations are the country will feel less divided politically, culturally and socially. This may make politicians more cooperative in solving problems and less partisan.
Eric Lefkofsky also serves numerous organizations within his hometown. This includes the Museum of Science and Industry, the Lurie Children’s Hospital of Chicago and World Business Chicago. In 2006, Eric Lefkofsky established the Lefkofsky Family Foundation. The main goal of the foundation is supporting other humanitarian groups in their work. They find organizations making a lasting and positive impact on the population and provide them with funding. This includes charter schools, theaters, community medical centers, political PACs, museums and so much more. The Lefkofsky Family Foundation focuses their finances on human rights, health, the fine arts, education and the performing arts.
New clinical trial results show that undergoing high-dose immunosuppressive therapy and then having the patient’s blood-forming stem cells transplanted brings on the reduction of relapsing-remitting multiple sclerosis (MS). MS is an autoimmune disease in which the central nervous system gets attacked by the immune system. The treatment is called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HTC). Five years after participants had received treatment; sixty-nine percent of them didn’t have any new brain lesions and did not experience symptoms of MS.
Studies have revealed that other methods of treatment have not been as successful as HDIT/HTC. The trial, named HALT-MS was funded by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID-sponsored Immune Tolerance Network (ITN) conducted the study, of which the five-year results appeared in the American Academy of Neurology’s journal Neurology. NIAID director Anthony S. Fauci said that the extended findings suggest that a one-time treatment with HDIT/HTC may be better than any long-term medication given to people with any type of MS. The purpose of the experiment was to remove the disease-causing cells and keep the immune system in its normal state.
Dr. Shiva Gopal Vasishita is a practicing neurologist at Voorhees, New Jersey who works with the Kennedy National Hospital. He is among the 34 doctors in the hospital who specialize in neurology. Dr. Shiva Vasishita has an experience of over 38 years of experience in his area of expertise. He received his medical degree from Government Medical School Nagpur in 1979.
Dr. Gopal Vasishita is a member of the practice group known as Eastern Neurodiagnostic Associates and is also an expert in psychiatry. Dr. Gopal Vasishita accepts various insurance plans which include: Horizon Blue Cross Blue Shield, Aetna, and Medicare. He is a certified neurologist, licensed to practice in New Jersey (his license number is 25MA55133). His current place of practice is 2301 Evesham Road, Pavilion 800 Suite 2009, Voorhees, NJ.